The discussion centres on GLP-1RA weight loss drugs and the internet trend of ‘micro-dosing’. An expert clarifies this is not a medically or legally valid approach, differentiating it from the approved ‘dose escalation’ method used to manage side effects. The expert states, “I do not think a micro-dosing for a weight loss drug or GFP-1 are either economically or legally a good approach.” This comes as the World Health Organization (WHO) adds GLP-1 drugs to its essential medicines list for both diabetes and obesity. This move could increase global access and lower costs. However, this endorsement is contrasted with ongoing lawsuits in some countries citing severe side effects, including vision loss. The conversation also explores the implications for India, where WHO’s listing could lead to price controls and the necessity for more robust, India-specific post-marketing surveillance data as usage grows. #weightloss #glp1 #microdosing #itwebvideos #mounjaro #obesity #diabetes #who #healthnews #sideeffects #drugsafety #essentialmeds #indiatoday #medicaladvice #pharma #publichealth
Subscribe to India Today for NEW VIDEOS EVERY DAY and make sure to enable Push Notifications so you’ll never miss a new video.
All you need to do is PRESS THE BELL ICON next to the Subscribe button!
India Today TV is India’s leading English News Channel. India Today YouTube channel offers latest news videos on Politics, Business, Cricket, Bollywood, Lifestyle, Auto, Technology, Travel, Entertainment and a lot more.
Stay tuned for latest updates and in-depth analysis of news from India and around the world!
WhatsApp Channel: https://whatsapp.com/channel/0029Va2AnW3JENxxg7OuJv00
Download App: https://indiatoday.link/wHaj
Follow us: Official website: https://www.indiatoday.in/
Twitter: https://twitter.com/IndiaToday
Facebook: https://www.facebook.com/IndiaToday
